Table 7.
Drug-eluting stents (DES) with fully biodegradable scaffolds and coatings.
| Trade Name | Stent Platform | Polymer System | Drug | Drug Release (DAYS) | Manufacturer | APPROVAL |
|---|---|---|---|---|---|---|
| AbsorbTM | PLLA | PDLLA | Evorolimus | (28) 80% | Abbot Vascular (Northbrook, IL) | FDA approval |
| DESolve® | PLLA | PLLA | NovolimusTM | (180–270) 100% | Elixir® (Milpitas, CA) | CE approval |
| Dreams I | Mg | PLGA | Paclitaxel | (90) 100% | Biotronik (Poznań, Poland) | Phase 0 NCT01168830 |
| Dreams II | Mg | PLLA | Sirolimus | n.a. | Biotronik (Poznań, Poland) | Phase 0 NCT01960504 |
| ReZolve2 | PTD-PC | n.a. | Sirolimus | (90)~100% | REVA (San Diego, CA) | Clinical study NCT01845311 |
Mg: magnesium, PTD-PC: poly-tyrosine-derived polycarbonate, n.a.: not applicable.